AviadoBio is proud to announce a successful funding round that raised an impressive $72,000,000, marking a significant milestone in our mission to revolutionize treatments for neurodegenerative diseases. At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for those living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This newly secured capital will empower our innovative work in gene therapy and precision delivery systems, allowing us to further develop and scale our proprietary platforms designed to overcome the formidable challenges of delivering the right treatment to the right location within the brain. Our approach is firmly rooted in neuroanatomy-led research, an initiative born from pioneering studies at King’s College London and the UK Dementia Research Institute, which enables us to maximize the therapeutic potential of revolutionary gene therapies. The infusion of funds not only underscores the confidence that investors place in our strategic vision but also accelerates our pipeline of novel therapies aimed at halting, and potentially reversing, the progression of debilitating neurodegenerative conditions. In the coming months, this funding will support advanced clinical research, expand our state-of-the-art manufacturing capabilities, and drive further collaboration with leading scientific and clinical experts. As we embark on this exciting chapter, AviadoBio is more committed than ever to transforming our deep understanding of the brain into meaningful, transformative treatments, offering hope to patients and families affected by FTD and ALS worldwide.
AviadoBio Secures $72M in Series B Funding to Accelerate Breakthrough Gene Therapy for FTD and ALS
Get the full AviadoBio company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
BioStem Technologies
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE, VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.
$2.5M Unknown
today
Edify Systems
When you're running 10+ stores, the cracks in your operations become expensive. Inconsistent stock levels across sites, manual processes that don't scale, food waste that eats into margins, and zero real time visibility for the ops team. That's what Edify solves. Our AI powered platform gives operations leaders a single system to manage inventory, plan production, and report across their entire estate, whether that's 20 locations or 500. Built in intelligence surfaces the insights that matter, so your team spends less time in spreadsheets and more time running operations. What we cover: Inventory management across all sites. AI driven production planning and prep workflows. Operational reporting and real time visibility. Multi location scalability built in from day one. We work with QSR brands and multi site coffee chains who have outgrown spreadsheets and fragmented systems but need something purpose built for high volume, multi unit operations. If your back of house is holding back your growth, we should talk.
$4.0M Seed
today
Generalist
Generalist is an AI robotics company building general intelligence for the physical world. The founding team includes engineers from OpenAI, Google DeepMind, and Boston Dynamics. The company embraces both large-scale AI and robotics as core to its DNA.
$400.0M Unknown
today
Scotch
From neighborhood stores to destination warehouses, liquor retailers of all sizes have been held back by manual tasks, slow systems and limited business intelligence. So we decided to build something better — smarter software that saves time and improves margins so independent retailers could focus on their customers, not manually managing inventory.
$20.0M Series a
today
Kempfer / K Creative Office
Based in São Paulo, we specialize in social media creation and content, delivering creative solutions that connect, engage, and inspire Com sede em São Paulo, somos especialistas em criação e conteúdo para social media, entregando soluções criativas que conectam, envolvem e inspiram.
$1.3M Unknown
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  ONA Therapeutics Spain | Series b | $86.6M | today |
| 2 |  GR3N SA Switzerland | Series b | $15.5M | 1d ago |
| 3 |  701x United States | Series b | $10.0M | 1d ago |
| 4 |  Wordsmith AI United States | Series b | $70.0M | 1d ago |
| 5 |  MJOLNIR SPACEWORKS Japan | Series b | $11.1M | 2d ago |